ABEO (abeonatherapeutics.com) יחס שווי שוק לשווי בספרים

Abeona Therapeutics (ABEO) aims for dominance in the epidermolysis bullosa therapy niche through the launch of the high-cost drug Pz-cel. The technology stack is based on automated bioreactors, although final drug verification requires physician involvement, and the indicator stands at 2.00. This price action chart demonstrates the asset's market quotes. Production capacities are regularly updated to comply with global purity standards for the release of cellular products.

The stability of the R&D core and the retention of rare disease experts create the valuation foundation for Abeona Therapeutics (ABEO), which is reflected in the market-to-book value premium. This indicator compares the current market price to net assets, allowing investors to assess the degree of business overvaluation and identify manipulative spikes that may signal hidden vulnerabilities in the model.